Education
About Us
Working with TipRanks
Follow Us
Harmony Biosciences Holdings (HRMY)
NASDAQ:HRMY
HRMY Analyst Ratings
Moderate Buy
4 Buy
3 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
HRMY Stock 12 Month Forecast
Average Price Target
$41.25
▲(46.33% Upside)
| Highest Price Target$62.00 | Average Price Target$41.25 | Lowest Price Target$25.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$55
Buy
95.10%
Upside
Reiterated
02/25/26
We assess Harmony using a risk-adjusted discounted cash flow (DCF)- and sum-of-the-parts (SOTP)- based methodology on free cash flow to the firm (FCFF) and net income per asset, respectively. We assign probabilities of success to pitolisant GR in NT1, NT2, and IH of 60%, pitolisant HD in NT1, NT2, and IH of 60%, EPX100 in Dravet syndrome of 80%, and EPX100 in Lennox-Gastaux syndrome of 80%. Although pitolisant-GR is expected to have a unique brand, we expect pricing to be similar to pitolisant-IR. We employ a 12% discount rate and a terminal multiple of 6.0x.
Mizuho Securities
$50
Buy
77.37%
Upside
Reiterated
02/25/26
Deutsche Bank
$31→$30
Hold
6.42%
Upside
Reiterated
02/25/26
Truist Financial
$25
Hold
-11.32%
Downside
Reiterated
02/25/26
Oppenheimer
$62
Buy
119.94%
Upside
Reiterated
02/25/26
Bank of America Securities
$32→$28
Sell
-0.67%
Downside
Reiterated
02/24/26
Needham
$46→$44
Buy
56.08%
Upside
Reiterated
02/24/26
Piper Sandler
$48
Buy
70.27%
Upside
Reiterated
09/25/25
Cantor Fitzgerald
$54→$50
Buy
77.37%
Upside
Reiterated
09/24/25
Goldman Sachs
$33
Hold
17.06%
Upside
Initiated
07/10/25
LifeSci Capital
$61
Buy
116.39%
Upside
Reiterated
04/08/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$55
Buy
95.10%
Upside
Reiterated
02/25/26
We assess Harmony using a risk-adjusted discounted cash flow (DCF)- and sum-of-the-parts (SOTP)- based methodology on free cash flow to the firm (FCFF) and net income per asset, respectively. We assign probabilities of success to pitolisant GR in NT1, NT2, and IH of 60%, pitolisant HD in NT1, NT2, and IH of 60%, EPX100 in Dravet syndrome of 80%, and EPX100 in Lennox-Gastaux syndrome of 80%. Although pitolisant-GR is expected to have a unique brand, we expect pricing to be similar to pitolisant-IR. We employ a 12% discount rate and a terminal multiple of 6.0x.
Mizuho Securities
$50
Buy
77.37%
Upside
Reiterated
02/25/26
Deutsche Bank
$31→$30
Hold
6.42%
Upside
Reiterated
02/25/26
Truist Financial
$25
Hold
-11.32%
Downside
Reiterated
02/25/26
Oppenheimer
$62
Buy
119.94%
Upside
Reiterated
02/25/26
Bank of America Securities
$32→$28
Sell
-0.67%
Downside
Reiterated
02/24/26
Needham
$46→$44
Buy
56.08%
Upside
Reiterated
02/24/26
Piper Sandler
$48
Buy
70.27%
Upside
Reiterated
09/25/25
Cantor Fitzgerald
$54→$50
Buy
77.37%
Upside
Reiterated
09/24/25
Goldman Sachs
$33
Hold
17.06%
Upside
Initiated
07/10/25
LifeSci Capital
$61
Buy
116.39%
Upside
Reiterated
04/08/25
Best Analysts Covering Harmony Biosciences Holdings
3 Months
xxx
Success Rate
9/14 ratings generated profit
Average Return
+6.14%
reiterated a xxx
rating 11 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +6.14% per trade.
1 Year
Success Rate
7/15 ratings generated profit
Average Return
-2.34%
reiterated a buy rating 5 months ago
Copying David Amsellem's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of -2.34% per trade.
2 Years
xxx
Success Rate
4/15 ratings generated profit
Average Return
-12.23%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 26.67% of your transactions generating a profit, with an average return of -12.23% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
HRMY Analyst Recommendation Trends
Rating
Oct 25
Nov 25
Dec 25
Jan 26
Feb 26
Strong Buy
9
10
5
4
3
Buy
37
51
41
35
17
Hold
1
1
0
0
5
Sell
1
2
1
1
1
Strong Sell
0
0
0
0
0
total
48
64
47
40
26
Each month's total comprises the sum of three months' worth of ratings.
HRMY Financial Forecast
HRMY Stock Forecast FAQ
What is HRMY’s average 12-month price target, according to analysts?
Based on analyst ratings, Harmony Biosciences Holdings’s 12-month average price target is 41.25.
What is HRMY’s upside potential, based on the analysts’ average price target?
Harmony Biosciences Holdings has 46.33% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is HRMY a Buy, Sell or Hold?
Harmony Biosciences Holdings has a consensus rating of Moderate Buy which is based on 4 buy ratings, 3 hold ratings and 1 sell ratings.
What is Harmony Biosciences Holdings’s price target?
The average price target for Harmony Biosciences Holdings is 41.25. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $62.00 ,the lowest forecast is $25.00. The average price target represents 46.33% Increase from the current price of $28.19.
The highest analyst price target is $62.00 ,the lowest forecast is $25.00. The average price target represents 46.33% Increase from the current price of $28.19.
What do analysts say about Harmony Biosciences Holdings?
Harmony Biosciences Holdings’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of HRMY?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.